Literature DB >> 17268367

[Primitive metastasizing bronchial carcinoid with long survival].

N Bouvier1, V Zengerling, A Halley, V Le Pennec, J P Le Rochais, J Madelaine, F Galateau-Salle, E Bergot, G Zalcman.   

Abstract

BACKGROUND: Metastatic bronchial carcinoid tumours are rare but some patients have a prolonged survival. A new functional imagery now makes it possible to supplement the assessment of the extent of disease. OBSERVATION: A 57 year old patient was referred for dyspnoea on exertion revealing an upper left lobar tumour, with carcinoid syndrome. The assessment enabled to find out a bronchial carcinoid tumour with liver and bone metastases, highlighted by positron-emission tomography and pentetreotide SPECT. A chemotherapy proved to be ineffective and upper left lobectomy was carried out because of the risk of pulmonary atelectasis. The patient was treated by somatostatin analogues then underwent liver transcatheter arterial chemo-embolization. The patient was alive 44 months after diagnosis (56 months after first computed tomography).
CONCLUSION: Metastatic bronchial carcinoid tumours are rare. They keep a metastatic potential, the histological type remaining the major prognosis factor. Carcinoid syndrome is suggestive. The assessment of extra-thoracic disease extent benefits by contribution of new functional imagery techniques such as the pentetreotide SPECT and positron-emission tomography. The management is essentially symptomatic since there is no effective chemotherapy. However survival can be prolonged, even in multimetastatic patients.

Entities:  

Mesh:

Year:  2007        PMID: 17268367

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  2 in total

1.  [Localised bronchiectasis revealing carcinoid tumor].

Authors:  Hind Janah; Hasna Jabri; Régis Gothard Bopaka; Wiam El Khattabi; Hicham Afif
Journal:  Pan Afr Med J       Date:  2016-07-28

Review 2.  Focus on treatment of lung carcinoid tumor.

Authors:  Elise Noel-Savina; Renaud Descourt
Journal:  Onco Targets Ther       Date:  2013-10-25       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.